These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37872396)

  • 1. Fifteen years of real-world data on the use of vigabatrin in individuals with infantile epileptic spasms syndrome.
    Kuchenbuch M; Lo Barco T; Chemaly N; Chiron C; Nabbout R
    Epilepsia; 2024 Feb; 65(2):430-444. PubMed ID: 37872396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of vigabatrin in the treatment of infantile epileptic spasms syndrome: A systematic review and meta-analysis.
    Xu Z; Gong P; Jiao X; Niu Y; Wu Y; Zhang Y; Chang X; Yang Z
    Epilepsia Open; 2023 Jun; 8(2):268-277. PubMed ID: 36740237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epileptic spasms relapse is associated with response latency but not conventional attributes of post-treatment EEG.
    Deckard E; Sathe R; Tabibzadeh D; Terango A; Groves A; Rajaraman RR; Nariai H; Hussain SA
    Epilepsia Open; 2024 Jun; 9(3):1034-1041. PubMed ID: 38588009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A lack of clinically apparent vision loss among patients treated with vigabatrin with infantile spasms: The UCLA experience.
    Schwarz MD; Li M; Tsao J; Zhou R; Wu YW; Sankar R; Wu JY; Hussain SA
    Epilepsy Behav; 2016 Apr; 57(Pt A):29-33. PubMed ID: 26921595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is the optimal duration for vigabatrin monotherapy in patients with infantile spasms: 6 months or longer?
    Desnous B; Lenoir M; Bitton JY; Arbour M; Villeneuve N; Whiting S; Mohammed I; Wirrell EC; Bello-Espinosa L; Ronen GM; Lortie A; Birca A
    Seizure; 2021 Oct; 91():503-506. PubMed ID: 34371246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High vigabatrin dosage is associated with lower risk of infantile spasms relapse among children with tuberous sclerosis complex.
    Hussain SA; Schmid E; Peters JM; Goyal M; Bebin EM; Northrup H; Sahin M; Krueger DA; Wu JY;
    Epilepsy Res; 2018 Dec; 148():1-7. PubMed ID: 30296632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-life data comparing the efficacy of vigabatrin and oral steroids given sequentially or combined for infantile epileptic spasms syndrome.
    Dozieres-Puyravel B; Nasser H; Mauvais FX; De Saint Martin A; Perriard C; Di Meglio C; Cances C; Hachon-LE Camus C; Milh M; Auvin S
    Eur J Paediatr Neurol; 2024 Jan; 48():61-66. PubMed ID: 38041897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vigabatrin therapy in infantile spasms.
    Kankirawatana P; Raksadawan N; Balangkura K
    J Med Assoc Thai; 2002 Aug; 85 Suppl 2():S778-83. PubMed ID: 12403260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology and outcome of infantile spasms in Denmark in 1996-2019.
    Winther CCH; Klein-Petersen AW; Preel M; Kofoed IR; Bo Nissen I; Axelgaard S; Green J; Miranda MJ; Hoei-Hansen CE
    Seizure; 2024 Aug; 120():173-179. PubMed ID: 39029407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms.
    Appleton RE; Peters AC; Mumford JP; Shaw DE
    Epilepsia; 1999 Nov; 40(11):1627-33. PubMed ID: 10565592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of vigabatrin in patients with tuberous sclerosis complex and infantile epileptic spasm syndrome: a systematic review.
    Prezioso G; Chiarelli F; Matricardi S
    Expert Rev Neurother; 2023; 23(7):661-671. PubMed ID: 37243682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infantile spasms in Down syndrome: good response to a short course of vigabatrin.
    Nabbout R; Melki I; Gerbaka B; Dulac O; Akatcherian C
    Epilepsia; 2001 Dec; 42(12):1580-3. PubMed ID: 11879370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epileptic spasms in tuberous sclerosis complex.
    Hsieh DT; Jennesson MM; Thiele EA
    Epilepsy Res; 2013 Sep; 106(1-2):200-10. PubMed ID: 23796861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of vigabatrin therapy for tuberous sclerosis with infantile spasms].
    Suzuki-Muromoto, S; Uematsu M; Sato H; Numata-Uematsu Y; Nakayama T; Kiluchi A; Kobayashi T; Hino-Fukuyo N; Kure S
    No To Hattatsu; 2016 Nov; 48(6):413-9. PubMed ID: 30010289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study.
    Vigevano F; Cilio MR
    Epilepsia; 1997 Dec; 38(12):1270-4. PubMed ID: 9578521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vigabatrin-related adverse events for the treatment of epileptic spasms: systematic review and meta-analysis.
    Biswas A; Yossofzai O; Vincent A; Go C; Widjaja E
    Expert Rev Neurother; 2020 Dec; 20(12):1315-1324. PubMed ID: 33078964
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of infantile spasms: results of a population-based study with vigabatrin as the first drug for spasms.
    Granström ML; Gaily E; Liukkonen E
    Epilepsia; 1999 Jul; 40(7):950-7. PubMed ID: 10403219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of infantile spasms with vigabatrin as first-line therapy and in monotherapy: apropos of 70 infants].
    Villeneuve N; Soufflet C; Plouin P; Chiron C; Dulac O
    Arch Pediatr; 1998 Jul; 5(7):731-8. PubMed ID: 9759271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term analysis of adrenocorticotropic hormone monotherapy for infantile epileptic spasms syndrome with periventricular leukomalacia.
    Matsuura R; Hamano SI; Hirata Y; Takeda R; Takeuchi H; Koichihara R; Kikuchi K; Oka A
    Seizure; 2023 Jul; 109():40-44. PubMed ID: 37207538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of vigabatrin-associated brain abnormalities on MRI in the treatment of infantile spasms is dose-dependent.
    Hussain SA; Tsao J; Li M; Schwarz MD; Zhou R; Wu JY; Salamon N; Sankar R
    Epilepsia; 2017 Apr; 58(4):674-682. PubMed ID: 28230253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.